April price cut hits Japanese growth
This article was originally published in Scrip
Japan's total prescription market grew by a modest 2.4% in the three months to June 30th, rising to ¥2,046.8 billion ($18.85 billion) at reimbursement prices but constrained by the regular biennial April 1st general price cut. This saw reimbursement levels cut by an average of 5.2%, with one-off reductions of around 10% for fast-growing angiotensin II antagonists.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.